Given a question and a context passage, generate the answer having the word or phrase from the context passage. Here, the answer should be a shortest continous span from the passage.

[Q]: Context: The Narym River is a river in the Eastern Kazakhstan, a tributary of the Irtysh River, originating at the junction of the ridges Narym and Sarymsakty of wetland formed by the mountain runoff streams.
Question: The body of water that Narym River is near is what?
[A]: irtysh river

[Q]: Context: To determine the efficacy and safety of different doses of secukinumab, a fully human monoclonal antibody for targeted interleukin-17A blockade, in patients with noninfectious uveitis. Three multicenter, randomized, double-masked, placebo-controlled, dose-ranging phase III studies: SHIELD, INSURE, and ENDURE. A total of 118 patients with Behcet's uveitis (SHIELD study); 31 patients with active, noninfectious, non-Behcet's uveitis (INSURE study); and 125 patients with quiescent, noninfectious, non-Behcet's uveitis (ENDURE study) were enrolled. After an initial subcutaneous (s.c.) loading phase in each treatment arm, patients received s.c. maintenance therapy with secukinumab 300 mg every 2 weeks (q2w), secukinumab 300 mg monthly (q4w), or placebo in the SHIELD study; secukinumab 300 mg q2w, secukinumab 300 mg q4w, secukinumab 150 mg q4w, or placebo in the INSURE study; or secukinumab 300 mg q2w, secukinumab 300 mg q4w, secukinumab 150 mg q4w, or placebo in the ENDURE study. Reduction of uveitis recurrence or vitreous haze score during withdrawal of concomitant immunosuppressive medication (ISM). Other end points included best-corrected visual acuity, ISM use (expressed as a standardized ISM score), and safety outcomes. After completion or early termination of each trial, there were no statistically significant differences in uveitis recurrence between the secukinumab treatment groups and placebo groups in any study. Secukinumab was associated with a significant reduction in mean total post-baseline ISM score (P = 0.019; 300 mg q4w vs. placebo) in the SHIELD study. Likewise, secukinumab was associated with a greater median reduction in ISM score versus placebo in the INSURE study, although no statistical analysis of the difference was conducted because of the small sample size. Overall, there was no loss in visual acuity reported in any treatment group during follow-up in all 3 studies. According to descriptive safety statistics, the frequencies of ocular and nonocular adverse events seemed to be slightly higher among secukinumab groups versus placebo across the 3 studies. The primary efficacy end points of the 3 studies were not met. The secondary efficacy data from these studies suggest a beneficial effect of secukinumab in reducing the use of concomitant ISM.
Question: Which molecule is targeted by a monoclonal antibody Secukinumab?
[A]: interleukin-17a

[Q]: Context: As of the census of 2000, there were 445,342 people, 169,162 households, and 114,015 families residing in the county. The population density was 615 people per square mile (238/km). There were 178,913 housing units at an average density of 247 per square mile (95/km). The racial makeup of the county was 82.19% Race (United States Census), 1.15% Race (United States Census) or Race (United States Census), 0.65% Race (United States Census), 6.68% Race (United States Census), 0.30% Race (United States Census), 5.86% from Race (United States Census), and 3.17% from two or more races. 11.17% of the population were Race (United States Census) or Race (United States Census) of any race. 17.2% were of German American, 9.9% English American, 8.2% Irish American, and 6.7% Americans ancestry. 81.7% spoke only English at home, while 9.6% spoke Spanish and 1.2% Vietnamese.
Question: Which group from the census in the county is smaller: German American or English American?
[A]:
english american